Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 4/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | F12 | P00748 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807357 | 0.90 | TRPC5 (0.51) | TRPC5PARP1TNKS2PARP2MKNK1 | |
| SCHEMBL21807252 | 0.89 | PARP1 (0.40) | TRPC5PARP1TNKS2PARP2MKNK1 | |
| SCHEMBL21807251 | 0.83 | TRPC5 (0.44) | TRPC5PARP1TNKS2PARP2ESR2 | |
| SCHEMBL21807841 | 0.82 | DNMT3A (0.47) | TRPC5MKNK1METMAPTACACB | |
| SCHEMBL24535151 | 0.79 | PARP1 (0.45) | PARP1TNKS2PARP2MKNK1ESR2 | |
| SCHEMBL22413405 | 0.78 | TRPC5 (0.42) | TRPC5PARP1TNKS2PARP2MKNK1 | |
| SCHEMBL28577030 | 0.78 | TRPC5 (0.54) | TRPC5P2RX7 | |
| SCHEMBL4311781 | 0.78 | MTOR (0.41) | MKNK1ESR2HPGDSMTOR | |
| SCHEMBL21807319 | 0.77 | TRPC5 (0.39) | TRPC5PARP1TNKS2PARP2MKNK1 | |
| SCHEMBL21807317 | 0.77 | TRPC5 (0.46) | TRPC5PARP1TNKS2PARP2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113939295-B | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4414365-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-01-27 | — | — | US | disclosed |
| EP-3941475-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3852533-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11046690-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046690-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2020191056-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191056-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-09-10 | — | — | US | disclosed |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-09-10 | — | — | US | disclosed |
| US-10654850-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654850-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200102301-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-04-02 | — | — | US | disclosed |
| WO-2020061162-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | TRPC5 2486/4885PARP1 2824/4885TNKS2 2412/4885 |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | TRPC5 3626/4885PARP1 3410/4885TNKS2 2308/4885 |
| US-20200102301-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | TRPC5 2486/4885PARP1 2824/4885TNKS2 2412/4885 |
| US-11046690-B2 | Pyridazinones and methods of use thereof | ATP6V1B1, GLS, REN | TRPC5 2486/4885PARP1 2824/4885TNKS2 2412/4885 |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | TRPC5 2486/4885PARP1 2824/4885TNKS2 2412/4885 |
| US-10654850-B2 | Pyridazinones and methods of use thereof | ATP6V1B1, GLS, REN | TRPC5 2486/4885PARP1 2824/4885TNKS2 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.